Saved in this browser. Sign in to sync across devices.
Care distinction: Deep brain stimulation involves surgically implanted electrodes. It is not the same as noninvasive transcranial magnetic stimulation (TMS). DBS for depression is investigational, whereas some TMS protocols have FDA-authorized uses for depression. This study did not change those indications.
What did the researchers do?
Investigators pooled data from 131 adults with treatment-resistant depression who had received bilateral subcallosal cingulate DBS in three independent cohorts. The team retrospectively reconstructed the regions activated by each person's stimulation settings and compared brain-connection maps with changes on the Hamilton Depression Rating Scale (HAM-D). A responder was defined as having at least a 50% reduction in the score.
TYPE OF EVIDENCE
Retrospective, peer-reviewed
Investigators looked back at existing treated cohorts. No new randomization or comparison with sham stimulation was performed for this analysis.
PATHWAYS
Connections mattered
Responders' stimulation patterns were less spatially variable. The left cingulum bundle and medial uncinate fasciculus were particularly relevant to the observed association.
POTENTIAL IMPLICATION
More individualized targeting
Connectome-informed placement may help future teams test whether activating particular pathways predicts sustained improvement.
NOT ESTABLISHED
No new treatment authorization
The study did not demonstrate that a personalized DBS strategy outperforms standard care, or identify a validated way to select patients.
Why the findings matter
Two electrodes placed in roughly similar anatomical locations may engage different fiber pathways in different people. Brain-connection mapping offers one way to investigate why some recipients show sustained symptom improvement while others do not. It is a promising approach to future clinical-trial design, not a ready-to-use diagnostic test or a guarantee of response.
How is DBS different from TMS?
TMS uses magnetic pulses delivered from outside the skull; certain devices and protocols have FDA-authorized uses for depression. DBS involves surgery to implant electrodes that stimulate deep brain circuits. The burdens, risks and regulatory statuses are very different. Approval of a brain-stimulation device for one condition does not mean it is established for another.
What must be tested next?
Prospective, ideally randomized comparisons are needed to determine whether connectivity-guided DBS improves symptoms and everyday functioning more reliably than alternative targeting or usual care, and to evaluate risks, durability and patient selection. This retrospective association alone cannot establish treatment efficacy.
Questions people can ask their care team
- Which established treatments and noninvasive options have evidence for this specific diagnosis?
- If discussing a clinical trial, what is investigational, what procedures are involved and what are the safety safeguards?
- Are outcomes measured beyond symptom scores—for example, daily functioning and quality of life?
- How would eligibility, long-term follow-up, device maintenance and other risks be explained?
From research map to clinical benefit is a major step
For now, connectome-guided DBS is a hypothesis to test rigorously in depression research. People should not seek an invasive brain-stimulation procedure because of a research announcement or change established treatment without a qualified clinician.
Original research and clinical context
- Song et al. — American Journal of Psychiatry, October 1, 2026 ↗
Peer-reviewed original retrospective analysis across 131 recipients of subcallosal cingulate DBS.
- PubMed — original study abstract, PMID 42816827 ↗
Methods, three-cohort population, response definition and authors' conclusions.
- Mount Sinai — research context, October 13, 2026 ↗
Institutional explanation of the connections studied; not a new efficacy trial.
- NIMH — Brain Stimulation Therapies ↗
Current clinical versus investigational brain stimulation uses.
Sources checked October 17, 2026. Educational editorial draft; independent clinical review pending. Brain-stimulation indications and study status can change.